- Home
- ARQT
as of 03-10-2026 2:58pm EST
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 3.3B | IPO Year: | 2020 |
| Target Price: | $31.86 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.13 | EPS Growth: | 88.79 |
| 52 Week Low/High: | $11.86 - $31.77 | Next Earning Date: | 05-25-2026 |
| Revenue: | $376,072,000 | Revenue Growth: | 91.34% |
| Revenue Growth (this year): | 34.46% | Revenue Growth (next year): | 29.77% |
| P/E Ratio: | -185.31 | Index: | N/A |
| Free Cash Flow: | -6311000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Arcutis Biotherapeutics Inc. (ARQT)
See Remarks
Avg Cost/Share
$25.59
Shares
8,733
Total Value
$220,943.38
Owned After
137,125
See Remarks
Avg Cost/Share
$25.54
Shares
6,287
Total Value
$158,319.84
Owned After
121,150
See Remarks
Avg Cost/Share
$25.54
Shares
37,349
Total Value
$940,527.77
Owned After
785,957
See Remarks
Avg Cost/Share
$25.54
Shares
3,687
Total Value
$92,846.26
Owned After
175,281
Director
Avg Cost/Share
$25.39
Shares
39,272
Total Value
$997,194.62
Owned After
22,123
SEC Form 4
Director
Avg Cost/Share
$25.65
Shares
10,000
Total Value
$256,518.00
Owned After
49,744
SEC Form 4
SVP Chief Financial Officer
Avg Cost/Share
$25.54
Shares
2,853
Total Value
$71,843.94
Owned After
87,754
See Remarks
Avg Cost/Share
$27.95
Shares
3,325
Total Value
$92,933.75
Owned After
137,125
SEC Form 4
See Remarks
Avg Cost/Share
$25.81
Shares
9,794
Total Value
$252,747.88
Owned After
121,150
SEC Form 4
See Remarks
Avg Cost/Share
$25.33
Shares
40,638
Total Value
$1,027,292.65
Owned After
137,125
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Matsuda Masaru | ARQT | See Remarks | Mar 2, 2026 | Sell | $25.59 | 8,733 | $220,943.38 | 137,125 | |
| Burnett Patrick | ARQT | See Remarks | Mar 2, 2026 | Sell | $25.54 | 6,287 | $158,319.84 | 121,150 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Mar 2, 2026 | Sell | $25.54 | 37,349 | $940,527.77 | 785,957 | |
| Edwards Larry Todd | ARQT | See Remarks | Mar 2, 2026 | Sell | $25.54 | 3,687 | $92,846.26 | 175,281 | |
| Leonard Keith R | ARQT | Director | Mar 2, 2026 | Sell | $25.39 | 39,272 | $997,194.62 | 22,123 | |
| Welgus Howard G. | ARQT | Director | Mar 2, 2026 | Sell | $25.65 | 10,000 | $256,518.00 | 49,744 | |
| Vairavan Latha | ARQT | SVP Chief Financial Officer | Mar 2, 2026 | Sell | $25.54 | 2,853 | $71,843.94 | 87,754 | |
| Matsuda Masaru | ARQT | See Remarks | Feb 27, 2026 | Sell | $27.95 | 3,325 | $92,933.75 | 137,125 | |
| Burnett Patrick | ARQT | See Remarks | Feb 4, 2026 | Sell | $25.81 | 9,794 | $252,747.88 | 121,150 | |
| Matsuda Masaru | ARQT | See Remarks | Feb 2, 2026 | Sell | $25.33 | 40,638 | $1,027,292.65 | 137,125 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 25, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 25, 2026 · 100% conf.
1D
-6.00%
$25.39
5D
-13.25%
$23.43
20D
-15.97%
$22.70
arqt-20260225FALSE000178730600017873062026-02-252026-02-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2026
ARCUTIS BIOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-39186 81-2974255
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
3027 Townsgate Road, Suite300 Westlake Village, CA 91361 (Address of principal executive offices, including Zip Code) Registrant’s telephone number, including area code: (805) 418-5006
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share
ARQT
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 25, 2026, Arcutis Biotherapeutics, Inc. (the “Company” or “Arcutis”) issued a press release relating to its financial results for the quarter ended December 31, 2025. The full text of the press release is furnished herewith as Exhibit 99.1. The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d) Exhibits.
Exhibit No. Description
99.1Press Release February 25, 2026.
104Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ARCUTIS BIOTHERAPEUTICS, INC.
February 25, 2026By: /s/ Latha Vairavan Latha Vairavan Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Oct 28, 2025
Q3 2025 Earnings
8-KOct 28, 2025
arqt-20251028FALSE000178730600017873062025-10-282025-10-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2025
ARCUTIS BIOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-39186 81-2974255
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
3027 Townsgate Road, Suite300 Westlake Village, CA 91361 (Address of principal executive offices, including Zip Code) Registrant’s telephone number, including area code: (805) 418-5006
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share
ARQT
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On October 28, 2025, Arcutis Biotherapeutics, Inc. (the “Company” or “Arcutis”) issued a press release to outline its strategy for driving sustainable growth and to announce its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished herewith as Exhibit 99.1. The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d) Exhibits.
Exhibit No. Description
99.1Press Release October 28, 2025.
104Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ARCUTIS BIOTHERAPEUTICS, INC.
October 28, 2025By: /s/ Latha Vairavan Latha Vairavan Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 6, 2025
Q2 2025 Earnings
8-KAug 6, 2025
arqt-20250806FALSE000178730600017873062025-08-062025-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025
ARCUTIS BIOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-39186 81-2974255
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
3027 Townsgate Road, Suite300 Westlake Village, CA 91361 (Address of principal executive offices, including Zip Code) Registrant’s telephone number, including area code: (805) 418-5006
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share
ARQT
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 6, 2025, Arcutis Biotherapeutics, Inc. (the “Company” or “Arcutis”) issued a press release relating to its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished herewith as Exhibit 99.1. The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d) Exhibits.
Exhibit No. Description
99.1Press Release August 6, 2025.
104Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ARCUTIS BIOTHERAPEUTICS, INC.
August 6, 2025By: /s/ Latha Vairavan Latha Vairavan Chief Financial Officer
Compare ARQT vs Leading Stocks
See how ARQT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ARQT Arcutis Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.